Medtronic PLC Company Profile (NYSE:MDT)

Medtronic PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

Medtronic PLC declared a quarterly dividend on Friday, June 23rd. Investors of record on Friday, July 7th will be paid a dividend of $0.46 per share on Wednesday, July 26th. This represents a $1.84 annualized dividend and a yield of 2.16%. The ex-dividend date is Wednesday, July 5th. This is a boost from Medtronic PLC's previous quarterly dividend of $0.43. View Medtronic PLC's Dividend History.

Medtronic PLC (NYSE:MDT) released its quarterly earnings data on Thursday, May, 25th. The company reported $1.33 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.31 by $0.02. The firm earned $7.92 billion during the quarter, compared to analyst estimates of $7.86 billion. Medtronic PLC had a net margin of 13.56% and a return on equity of 12.72%. The business's quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.27 EPS. View Medtronic PLC's Earnings History.

Medtronic PLC is scheduled to release their next quarterly earnings announcement on Tuesday, August, 22nd 2017. View Earnings Estimates for Medtronic PLC.

23 equities research analysts have issued 1 year price objectives for Medtronic PLC's shares. Their predictions range from $78.00 to $102.00. On average, they expect Medtronic PLC's share price to reach $89.26 in the next year. View Analyst Ratings for Medtronic PLC.

Here are some recent quotes from research analysts about Medtronic PLC stock:

• 1. Needham & Company LLC analysts commented, "F4Q17 revenue and EPS beat consensus and initial FY18 guidance was in line with consensus. Organic revenue growth was steady at 4.0% vs. 4.1% in F3Q17 with new products adding ~370 bps, emerging markets adding ~125 bps and services & solutions adding ~15 bps. Operating margin was above consensus and up 10 bps Y/Y (or 40 bps Y/Y CC). MDT’s product cycle remains strong with significant FY18 launches including: the Resolute Onyx DES, MiniMed 670G insulin pump, Signia powered stapler, new LigaSure instruments, Intellis spinal cord stimulator, Evolut PRO TAVR, and MRI CRT-P quadripolar system." (5/25/2017)
• 2. According to Zacks Investment Research, "Ahead of its fourth quarter fiscal 2017 result, we believe Medtronic will do well banking on strong performances of major business groups with sustainability across all regions. Earlier, the company observed solid growth trend in the U.S. on healthy global acceptance of its therapies. Particularly, we are optimistic about the gradually stabilizing trend in the global CRHF market. This yet-to-be-reported quarter is expected to be no exception to that. The company is currently on a spree of gaining regulatory approvals for its minimally invasive devices which is quite encouraging. On the flip side, escalating costs and expenses weighing on margins is a concern. Also, unfavorable foreign exchange continues to remain a drag. A dull fiscal guidance fails to indicate any chances of respite soon. This has been reflected in the company’s share price trend too. In the past one month, Medtronic consistently traded below the Zacks categorized Medical Product industry." (5/23/2017)
• 3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)
• 4. Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)
• 5. Evercore ISI analysts commented, "MDT started 2017 with a solid execution, highlighted by all around revenue beat and operating margins that were generally in line with ST (came in above us). The importance of this Q cannot be underestimated in our mind, as sentiment had turned negative (post a disappointing 1H) and the stock multiple (3-6x discount to peer group) was see-sawing precariously at ~15-16x P/E. While the bar had been lowered, MDT needed to deliver to flawless Q to instill investor confidence and start the path towards multiple correction (vs. group). The company began its first step, highlighted by a solid revenue beat, driven by high single digit growth in CR&HF. This is a key segment, and the ~8% growth should provide comfort against the bear thesis of competitive share losses / replacement cycle headwinds. We were also encouraged to see ~30% growth in TAVR, and a full rollout of the 34mm valve (launched only in 50% of centers) plus Intermediate Risk approval in early 2018 bodes well. Other key drivers in 2018 include the full commercial launch of 670G in Diabetes, Resolute Onyx launch, continued growth in AF, Link, DCBs, and the continued turnaround in Spine provides incremental confidence in MDT being able to sustain ~4% organic topline in the medium term. The second leg of value creation will rest on margin expansion, with the ST still skeptical of the company's ability to show margin expansion on a reported basis (including the impact of Fx hedges). We believe that the margin expansion thesis will play out in 2018, and will play a huge role in MDT's ability to close its P/E gap vs. peer group average. We expect this combination of a potential multiple reflation trade along with upside from capital deployment (incremental ~$3 Bn could potentially be accessible in near term post IRS settlement) to drive value for investors over the next 12 months." (2/21/2017)

Some companies that are related to Medtronic PLC include Roche Holding (RHHBY), Novartis AG (NVS), Pfizer (PFE), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), AbbVie (ABBV), Bayer AG (BAYRY), Celgene Corporation (CELG), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Gilead Sciences (GILD), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN) and Allergan PLC. (AGN).

Medtronic PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include Manning & Napier Advisors LLC (0.38%), Bank of Montreal Can (0.19%), Vontobel Asset Management Inc. (0.18%), Tesco Pension Investment Ltd (0.16%), RE Advisers Corp (0.10%) and APG Asset Management N.V. (0.10%). Company insiders that own Medtronic PLC stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic PLC.

Medtronic PLC's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Manning & Napier Advisors LLC, Vaughan Nelson Investment Management L.P., Vontobel Asset Management Inc., Swarthmore Group Inc., Sit Investment Associates Inc., Exxonmobil Investment Management Inc. TX and Hexavest Inc.. Company insiders that have sold Medtronic PLC stock in the last year include Bryan C Hanson, Hoedt Rob Ten, Hooman Hakami, Kendall J Powell, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic PLC.

Medtronic PLC's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Cornerstone Investment Partners LLC, Fisher Asset Management LLC, Aperio Group LLC, Tesco Pension Investment Ltd, Nisa Investment Advisors LLC, Factory Mutual Insurance Co. and Diversified Trust Co. Company insiders that have bought Medtronic PLC stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic PLC.

Shares of Medtronic PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Medtronic PLC stock can currently be purchased for approximately $85.17.